Trial Profile

A Phase ǀ Study to determine the Safety and Pharmacokinetics of the Human monoclonal Antibodies, VRC07-523LS and PGT121 administered subcutaneously to HIV negative Adults in South Africa

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PGT 121 (Primary) ; TMB-380 (Primary)
Indications HIV infections
Focus Adverse reactions; Pharmacodynamics
Acronyms CAP 012A; CAPRISA 012; CAPRISA 012A

Most Recent Events

16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
04 Feb 2022 Results published in the Journal of Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com